# Ehsan Jabbarzadeh

> Ehsan Jabbarzadeh is a Series A investor at Obsidio backing Biotechnology and Medical Device. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Obsidio](https://shizune.co/investors/profile/obsidio)
- Total investments: 5
- Last investment: May 2025
- Lead investor: 80%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/ehsanjabbarzadeh

Ehsan Jabbarzadeh is a Series A investor at Obsidio focused on Biotechnology and Medical Device. Ehsan Jabbarzadeh is the Founder and CEO at Obsidio.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 40% |
| Medical Device | 2 | 40% |
| Medical | 1 | 20% |
| mHealth | 1 | 20% |
| Health Care | 1 | 20% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 80% |
| Ireland | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| PATH EX | PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood, for the treatment of sepsis. Sepsis, a life-threatening condition that commonly presents itself as a blood-borne infection, is the number one cause of death in the ICU and is the largest cost on their healthcare system. PATH EXis taking a novel approach by capturing and removing intact bacteria from the blood rather than trying to kill the infection with broad spectrum antibiotics. The PATH EX device is effective regardless of bacteria type or drug resistance. The PATH EX technology has the potential to reduce diagnostic times, treatment costs, readmission rates, and sepsis related deaths. | $5M | Venture - Series Unknown | May 08, 2025 |  |
| CroíValve | CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $16M | Series B | Aug 07, 2024 |  |
| DeepCure | DeepCuris builds an AI engine for small-molecule drug discovery. | $24.6M | Series A | Apr 11, 2024 |  |
| Jana Care | Jana Care develops and manufactures Aina Blood Monitoring Device, a novel connected blood diagnostic device.Jana Care founders Sidhant Jena, Michal Depa, and Prof. Tarun Khanna were challenged by an enterprising physician-entrepreneur (Dr. Devi Shetty) to build a smartphone app for health workers to screen for Oral Cancer and CardiovascularDisease in remote rural communities in India. What started off as a side project during graduate school, became one of the largest chronic disease screening programs in the world and eventually led to Jana Care. | $6M | Series B | Nov 08, 2023 |  |
| Lucid Scientific | Lucid Scientific is a biotechnology tools company working to accelerate drug discovery and basic biological research by providing systems for real-time cellular analysis. It has invented an innovative new system for monitoring cell culture experiments. The company’s flagship technology, called RESIPHER, provides continuous and non-invasivemeasurement of oxygen consumption in a cell culture plate, then streams this information to a convenient web app. | $7M | Series A | Sep 05, 2023 |  |

5 of 5 investments shown.

## Co-investors
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 1 deal together
- [Ascentifi](https://shizune.co/investors/profile/ascentifi) — VC Fund, 1 deal together
- [Asha Impact](https://shizune.co/investors/profile/asha-impact) — VC Fund, 1 deal together
- [Atlantic Bridge University Fund](https://shizune.co/investors/profile/atlantic-bridge-university-fund) — VC Fund, 1 deal together
- [Broadview Ventures](https://shizune.co/investors/profile/broadview-ventures) — VC Fund, 1 deal together
- [Furthr](https://shizune.co/investors/profile/dublin-business-innovation-centre) — VC Fund, 1 deal together

## About Obsidio

VC Fund · Columbia, United States

Obsidio, Inc. is an early-stage medical device company pioneering a biomaterial platform technology to enable minimally-invasive occlusion of blood vessels anywhere in the body regardless of the patient’s coagulopathy. The technology can be used to control bleeding, close off vessels supplying blood to tumor, eliminate abnormal connections betweenarteries and veins, and treat aneurysms.

2 contacts available at Obsidio.

| Name | Title | Profile |
| --- | --- | --- |
| Ehsan Jabbarzadeh | Founder and CEO | https://shizune.co/investors/profile/ehsan-jabbarzadeh |
| Rahmi Oklu | Founder and Chief Medical Officer | https://shizune.co/investors/profile/rahmi-oklu-1fb6 |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Ehsan Jabbarzadeh invest in?

Ehsan Jabbarzadeh invests primarily in Biotechnology, Medical Device and Medical startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Ehsan Jabbarzadeh last invest?

The most recent investment recorded for Ehsan Jabbarzadeh closed in May 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co